

## GU ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/ Support	STUDY	O R P E E G N	ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs
						LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS			
SWOG	S1500-pRCC,Adv, Sunitinib vs MET inhib	1	Y 1 Sunitinib	180	18	12	7	4	1	0	07/25/2016	217	93
			2 Cabozantinib		15	9	6	3	1	0			
			3 Crizotinib		17	10	6	4	1	0			
			4 Savolitinib		17	12	5	4	2	0			
					67	43	24	15	5	0			
	S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	1	Y 1 TICE BCG	969	22	22	17	7	2	1	02/24/2017	145	65
			2 Tokyo-172 BCG		21	21	16	8	2	1			
			3 Prime + Tokyo-172 BCG		21	21	17	9	2	1			
					64	64	50	24	6	3			
	S1605-Blad, BCG-Unresponsive NMIBC, Atezolizumab	1	Y 1 Atezolizumab	148	30	30	24	15	3	2	03/13/2017	152	70
					30	30	24	15	3	2			
Yes	A031102-GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	1	E Total Registrations		2	1	0	0	0	0	11/23/2016	59	34
					2	1	0	0	0	0			
	EA8143-RCC, HR, Surg +/- Nivolumab (PROSPER)	0	E Total Registrations		7	7	7	4	1	0	09/29/2017		17
					7	7	7	4	1	0			
		1	E Total Registrations		6	6	6	3	1	0	09/29/2017		
					6	6	6	3	1	0			
	NRGGU002-Pros, RT + ADT After RP +/- Adj Docetaxel	1	E Total Registrations		1	1	1	0	0	0	08/24/2017		103
					1	1	1	0	0	0			
		2	E Total Registrations		1	1	1	0	0	0	08/24/2017		
					1	1	1	0	0	0			
No	EA8141-UTUC, HG, Chemo then Surg	1	E Total Registrations		8	2	0	0	0	0	02/23/2016	152	74
					8	2	0	0	0	0			
	R0924-Pros, NADT+WPRT vs. NADT+P&SV RT	1	E Total Registrations		64	28	17	9	3	2	11/25/2013		163
					64	28	17	9	3	2			